BSEM BioStem Technologies Inc

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

Pompano Beach, Fl., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. and its subsidiary Blue Tech Industries, Inc. (d/b/a BioStem Life Sciences), a Certified VOSB (Veteran-Owned Small Business), are proud to announce a 2021 Veterans Day Fundraiser to support America's VetDogs®. To honor those who have served our country, BioStem Technologies will be donating 10% of proceeds from all sales November 10-11th, 2021, to America's VetDogs®

The service dog programs of America's VetDogs® were created to provide enhanced mobility and renewed independence to United States veterans, active-duty service members, and first responders, allowing them to once again live with pride and self-reliance. America's VetDogs® specializes in placing highly skilled service and guide dogs with individuals suffering from physical injuries, PTSD, hearing and vision loss, and seizures. All services are provided by America's VetDogs® at no cost to the individual. 

"We are excited to support this amazing organization and its mission to help those who selflessly served our country live with independence and dignity. As a USMC veteran myself, I have witnessed many brothers and sisters dealing with issues ranging from mental health to physical disabilities resulting from their military service," stated Andrew Van Vurst, BioStem Technologies COO and Co-Founder. "BioStem has had the privilege of providing life-changing tissue allografts to the VA for the last few years, and we are honored once again to help those who serve us by providing quality care for our veterans."

For more information on America's VetDogs® or how you can help support this wonderful organization, please click .

About America's VetDogs®: Since 2003, America's VetDogs () has trained and placed guide and service dogs to provide independence, enhanced mobility, and companionship to veterans with disabilities from all eras. In 2015, VetDogs opened its programs to first responders, including fire, police, and emergency medical personnel. America's VetDogs is a 501(c)(3) not-for-profit organization founded by the Guide Dog Foundation and serves clients from across the United States. VetDogs relies on contributions from generous individuals, corporations, service clubs, and foundations to fund its mission to help those who have served our country live with dignity and independence. It costs over $50,000 to breed, raise, train, and place one assistance dog, but America's VetDogs provides its services completely free of charge to the individual. America's VetDogs has been accredited by both the International Guide Dog Federation and Assistance Dogs International. 

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local Microenvironment Activation®, or LMA®, uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value. 

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.

Phone: 954-380-8342

Website: 

Email: 

Twitter: @BSEM_Tech

Facebook: BioStem Technologies

Investor Relations:



(954) 380-8342



EN
01/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayes...

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis. FDA Commissioner, Dr. Martin Maka...

 PRESS RELEASE

BioStem Technologies Advances Entry into the Acute Wound Care Market w...

BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem’s position across hospital settings Barry Hassett promoted to Chief Commercial Officer Conference call scheduled for tomorrow, January 22nd at 8am ET POMPANO BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development...

 PRESS RELEASE

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medic...

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage Determinations (“LCD”) for skin substitute grafts/cellular and tissue-based ...

 PRESS RELEASE

BioStem Technologies Products Placed on “12-Month Status Quo Period” L...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates   POMPANO BEACH, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental...

 PRESS RELEASE

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foo...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our Veterans POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference held in Phoenix, Arizona, on December ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch